Kite Pharma
Santa Monica
California
United States
283 articles with Kite Pharma
-
Nkarta announced that two of its therapies have shown complete remission in patients with blood cancer. These results are the latest development in the treatment of difficult-to-treat blood cancers.
-
Kite Receives U.S. FDA Approval of New State-of-the-Art CAR T-Cell Therapy Manufacturing Facility in Maryland
4/19/2022
Kite’s Global CAR T-Cell Therapy Manufacturing Network Increasing Capacity by 50% to Meet Patient Demand for New Cancer Therapies.
-
Kite Pharma, a subsidiary of Gilead, announced that its Yescarta® has been approved by the U.S. Food and Drug Administration (FDA).
-
The FDA has a very busy week ending the month of March and moving into April, highlighted by a big AdCom vote on Amylyx's ALS candidate AMX0035 on March 30.
-
A new study published in the journal Nature found that two patients with leukemia who were treated with CAR T-cell therapy are still in remission 10 years later.
-
Gilead has announced they are pulling cancer drug Zydelig (idelalisib) off the market for certain types of cancer after failing to complete follow-up clinical trials to confirm efficacy and safety.
-
From the continuing fight against COVID-19 to new companies emerging in exciting therapeutic areas to the people who mattered most, here’s a look at just some of the biggest successes, most dramatic flops – and a few that fall somewhere in between.
-
The 63rd ASH Annual Meeting and Exposition is wrapping up today, with dozens providing updates on clinical trials and preclinical research. Here’s a highlight of just a few of those stories.
-
Yescarta® ZUMA-12 Study Demonstrates 78% Complete Response Rate as Part of First-Line Treatment in Newly Diagnosed High-Risk Large B-Cell Lymphoma
12/13/2021
Kite, a Gilead Company (Nasdaq: GILD), today announced primary results from ZUMA-12, a global, multicenter, single-arm, open-label Phase 2 study evaluating Yescarta® (axicabtagene ciloleucel) as part of first-line treatment in patients with high-risk large B-cell lymphoma (LBCL).
-
At the ASH meeting, Bristol Myers Squibb and Kite Pharma presented promising data from CAR-T programs aimed at relapsed or refractory large B-cell lymphoma.
-
Yescarta® CAR T-Cell Therapy Quadruples Median Event-Free Survival Duration Over Standard of Care in Second-Line Relapsed or Refractory Large B-Cell Lymphoma
12/11/2021
Kite, a Gilead Company, announced results from the primary analysis of ZUMA-7, a global Phase 3 study evaluating Yescarta® as a one-time infusion, in a head-to-head study against standard of care for adults with large B-cell lymphoma who relapsed or were refractory to first-line treatment.
-
Yescarta® Is First CAR T-cell Therapy to Report Five-Year Survival Data From Pivotal Study Showing Durable Long-Term Survival in Patients With Refractory Large B-cell Lymphoma
12/11/2021
Kite, a Gilead Company, announced five-year follow-up data from the pivotal ZUMA-1 trial of Yescarta® in adult patients with refractory large B-cell lymphoma.
-
Yescarta® Demonstrates Durable Two-Year Clinical Benefit in Adults With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma Including Follicular Lymphoma
12/11/2021
Kite, a Gilead Company, announced updated two-year results from ZUMA-5, a global, multicenter, single-arm, open-label Phase 2 study evaluating Yescarta® in adult patients with relapsed or refractory indolent non-Hodgkin lymphoma after at least two prior lines of therapy.
-
Gilead and Kite Oncology Demonstrate Broad Leadership in Cell Therapy and Expanding Blood Cancer Pipeline
11/4/2021
Gilead Sciences, Inc. (Nasdaq: GILD) and Kite today announced that data at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition (December 11-14)
-
BlueSphere Bio aims to overcome challenges in the CAR T space with a precision approach to T cell therapy.
-
FDA Action Alert: Mirum and Kite/Gilead
9/27/2021
The U.S. Food and Drug Administration is wrapping up the end of September and beginning October with two PDUFA dates. Here’s a look. -
Gilead won the most recent battle when a U.S. appeals court threw out a $1.2 billion ruling against the company.
-
Kite and Appia Bio Announce Collaboration to Research and Develop Allogeneic Cell Therapies for Cancer
8/5/2021
Kite, a Gilead Company (Nasdaq: GILD), and Appia Bio, Inc. today announced a collaboration and license agreement to research and develop HSC-derived cell therapies directed toward hematological malignancies.
-
BioNTech indicates the acquisition will add production capacity in support of U.S. clinical trials.
-
Clinical Catch-Up: June 28-July 2
7/6/2021
It was another busy week for clinical trial news ahead of the July 4 holiday in the U.S. Here’s a look.